The Future of Curation Is AI: Results by OpenX™ Improved Cost Per Acquisition in Ad Campaigns by 11x
PASADENA, Calif.--(BUSINESS WIRE)--May 21, 2025--
OpenX Technologies, Inc., one of the world's leading omnichannel supply-side platforms, today announced Results by OpenX™, a suite of approachable AI capabilities that harness deep neural networks to curate the highest-value inventory to deliver against specific advertiser goals.
In 2018, OpenX redefined curation by applying data and identity to deals via the largest independent supply-side identity graph. Today, this proprietary graph and its extensive partnerships power supply-side targeting at scale across high-quality digital media, including CTV, reaching 79% of streaming viewers. With a continued focus on unlocking value for the advertising ecosystem, OpenX has driven progress through strategic co-development with agency and publisher leaders.
OpenX is continuing its innovation in data-driven curation and supply-side targeting with the introduction of approachable AI-powered models, delivering measurable results for advertisers by training advanced machine-learning models to automatically identify and prioritize the best ad opportunities to deliver specific advertiser outcomes. With Engagement Models, the first capability in the Results by OpenX suite, a leading tech brand saw a 23x higher click-through rate and improved their cost per acquisition by 11x.
'AI-powered curation has the potential to help solve core challenges like streamlining operations, improving performance, and driving more efficient ad spend without leveraging personal identifiers,' says Ben Hovaness, Chief Media Officer at OMD Worldwide. 'Advancements like these are bringing the future forward, driving immediate improvements in bid rates and campaign performance for our clients — without compromising inventory quality.'
By analyzing billions of OpenRTB requests, OpenX's data science team built and trained advanced machine-learning models to score requests in real time based on predicted performance. These models send only the requests with a high likelihood of achieving a desired outcome within mid-funnel marketing activity. OpenX leverages its access to the entire universe of ad opportunities and trains models on the most comprehensive data set prior to any traffic shaping or other QPS constraints.
This ensures that the models understand the full universe of opportunities, and only send highly qualified requests from premium inventory to a specific buyer deal, resulting in more efficient and effective ad spend for advertisers and better cost management for DSPs. By sending only highly-qualified requests, Results by OpenX offers publishers improved revenue potential without sacrificing control.
'The curation advancements OpenX is building with its approachable AI solutions are delivering incremental revenue opportunities for future-forward publishers like us,' says Shobha Doshi, SVP, Programmatic Strategy and Operations at Raptive. 'Solutions that prioritize premium content while driving buyer outcomes are pushing the industry forward and creating a feedback loop of trust.'
'We believe that approachable AI is the future of programmatic curation,' says Ana Calabrese, VP, Head of Data Science at OpenX. 'AI's true value lies in recognizing patterns humans can't. Eventually, all inventory curation will be powered by machine learning. Today, our proprietary models help advertisers improve performance and efficiency by analyzing billions of bid requests and privacy-conscious signals.'
Results by OpenX leverages more than 40 ID-free signals in the bidstream, including contextual signals and non-sensitive information about the user and the ad that will be served. This approach is cookieless by design, and results in a curated deal ID that brands and agencies can then activate in their DSP of choice.
About OpenX
OpenX is an independent omni-channel supply-side platform (SSP) and a global leader in supply-side curation, transparency, and sustainability. Through its 100% cloud-based tech stack, OpenX powers advertising across CTV, app, mobile web, and desktop, enabling publishers to deliver marketers with improved performance and dynamic future-proofed solutions. With a 17-year track record of programmatic innovation, OpenX is a direct and trusted partner of the world's largest publishers, working with more than 150,000 premium publisher domains and over 100,000 advertisers. As the market leader in sustainability, OpenX was the first adtech company to be certified as CarbonNeutral™ and third-party verified for achieving its SBTi Net-Zero targets. Learn more at www.openx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250521979503/en/
CONTACT: Media
Zoey Larsen
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: DATA MANAGEMENT TECHNOLOGY PUBLISHING MARKETING ADVERTISING COMMUNICATIONS DIGITAL MARKETING SOFTWARE ARTIFICIAL INTELLIGENCE INTERNET MEDIA
SOURCE: OpenX Technologies, Inc.
Copyright Business Wire 2025.
PUB: 05/21/2025 08:05 AM/DISC: 05/21/2025 08:05 AM
http://www.businesswire.com/news/home/20250521979503/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Confused by latest order? How to calculate if your Jackson County assessment is within limits
KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
